JPH07500585A - 造影剤の副作用を防止するか又は治療するためのプロスタサイクリン誘導体の使用 - Google Patents

造影剤の副作用を防止するか又は治療するためのプロスタサイクリン誘導体の使用

Info

Publication number
JPH07500585A
JPH07500585A JP5507355A JP50735593A JPH07500585A JP H07500585 A JPH07500585 A JP H07500585A JP 5507355 A JP5507355 A JP 5507355A JP 50735593 A JP50735593 A JP 50735593A JP H07500585 A JPH07500585 A JP H07500585A
Authority
JP
Japan
Prior art keywords
group
hydroxy
contrast agents
nmr
ray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5507355A
Other languages
English (en)
Japanese (ja)
Inventor
クロップ，ライナー
ニーマー，ヴォルフガング
シペル，ヴォルフガング
クラウゼ，ヴェルナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of JPH07500585A publication Critical patent/JPH07500585A/ja
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
JP5507355A 1991-10-22 1992-10-22 造影剤の副作用を防止するか又は治療するためのプロスタサイクリン誘導体の使用 Pending JPH07500585A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4135193.2 1991-10-22
DE4135193A DE4135193C1 (enExample) 1991-10-22 1991-10-22
PCT/DE1992/000904 WO1993007875A1 (de) 1991-10-22 1992-10-22 Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln

Publications (1)

Publication Number Publication Date
JPH07500585A true JPH07500585A (ja) 1995-01-19

Family

ID=6443371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5507355A Pending JPH07500585A (ja) 1991-10-22 1992-10-22 造影剤の副作用を防止するか又は治療するためのプロスタサイクリン誘導体の使用

Country Status (11)

Country Link
US (1) US5814301A (enExample)
EP (1) EP0609336B1 (enExample)
JP (1) JPH07500585A (enExample)
AT (1) ATE162718T1 (enExample)
CA (1) CA2121838A1 (enExample)
DE (2) DE4135193C1 (enExample)
DK (1) DK0609336T3 (enExample)
ES (1) ES2114570T3 (enExample)
GR (1) GR3026324T3 (enExample)
PT (1) PT100997B (enExample)
WO (1) WO1993007875A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649476B2 (en) 2002-09-20 2017-05-16 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
EP0876140B1 (de) * 1996-01-25 2003-10-15 Schering Aktiengesellschaft Verbesserte kontrastmittenlösungen für die intravasale anwendung
CN1142781C (zh) * 1997-11-14 2004-03-24 联合治疗公司 9－脱氧－2′,9－α－亚甲基－3－氧杂－4,5,6－三去甲－3,7－(1′,3′－间亚苯基)－13,14－二氢－前列腺素F1在治疗外周血管疾病中的用途
CA2340375A1 (en) * 1999-06-14 2000-12-21 Hiroshi Maeda Agent for enhancing accumulation of drugs in tumor tissues
US20020147223A1 (en) * 1999-06-14 2002-10-10 Hiroshi Maeda Agent for enhancing accumulation of drugs in tumor tissues
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
CA2959852A1 (en) * 2003-05-22 2005-01-27 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態
CA3109851C (en) * 2018-09-14 2024-02-20 Pharmosa Biopharm Inc. Pharmaceutical composition for controlled release of weak acid drugs and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3204443A1 (de) * 1982-02-08 1983-08-18 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3427797A1 (de) * 1984-07-25 1986-02-06 Schering AG, 1000 Berlin und 4709 Bergkamen Zytoprotektive wirkung von prostacyclin-derivaten an leber, bauchspeicheldruese und niere
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
SE459806B (sv) * 1987-11-23 1989-08-07 Nils Enar Nilsson Anordning foer foerflyttning av en foersta del relativt en andra del
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649476B2 (en) 2002-09-20 2017-05-16 Bayer Intellectual Property Gmbh Medical device for dispersing medicaments

Also Published As

Publication number Publication date
DE4135193C1 (enExample) 1993-03-11
US5814301A (en) 1998-09-29
WO1993007875A1 (de) 1993-04-29
DE59209175D1 (de) 1998-03-05
DK0609336T3 (da) 1998-09-21
EP0609336A1 (de) 1994-08-10
EP0609336B1 (de) 1998-01-28
PT100997B (pt) 1999-10-29
PT100997A (pt) 1994-01-31
GR3026324T3 (en) 1998-06-30
ES2114570T3 (es) 1998-06-01
ATE162718T1 (de) 1998-02-15
CA2121838A1 (en) 1993-04-29

Similar Documents

Publication Publication Date Title
JP2758953B2 (ja) 血小板依存性動脈血栓症の予防方法
JPH09504274A (ja) 人工表面および血管面の血栓を予防する酸化窒素付加物の利用
WO2019141275A1 (zh) 用于靶向活化cd44分子的硅质体纳米载体递送系统、其制备方法和用途
Marsh et al. Serious complications after umbilical artery catheterization for neonatal monitoring
Borger et al. Decreased cerebral emboli during distal aortic arch cannulation: a randomized clinical trial
JPH07500585A (ja) 造影剤の副作用を防止するか又は治療するためのプロスタサイクリン誘導体の使用
JP2005519657A (ja) ナノ微粒子造影剤を用いた血管撮像の方法
JP4299967B2 (ja) 哺乳動物の管外組織への組成物の経管投与
US20050145258A1 (en) Composition, Method and Device for Blood Supply Fluctuation Therapy
Weisse et al. The fate of experimentally induced coronary artery thrombosis
Saltzman et al. The influence of different contrast media for cholegraphy on blood pressure and pulse rate
Manji et al. Survival from massive intraoperative pulmonary thromboembolism during orthotopic liver transplantation.
JP2002538226A (ja) Ｘａ因子阻害剤およびアスピリン、組織プラスミノーゲンアクチベータ（ＴＰＡ）、ＧＰＩＩｂ／ＩＩＩａ拮抗剤、低分子量ヘパリンまたはヘパリンの組合せ使用による血栓症の治療
Lindgren et al. Intravascular erythrocyte aggregation after intravenous injection of contrast media
Nishiwaki et al. Renal microcirculation in experimental acute pancreatitis of dogs
JP3110931B2 (ja) 平滑筋細胞増殖抑制作用を有するアルガトロバン製剤
Riess et al. Rhabdomyolysis following cardiopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia
US6231847B1 (en) Method of treating vascular proliferative responses
Sabbah et al. Coronary arteriography in dogs following blunt cardiac trauma: a longitudinal assessment
Whisson et al. The effect of intracarotid nonionic contrast media on the blood-brain barrier in acute hypertension.
Inui et al. Effect of methylprednisolone and prostacyclin on bronchial perfusion in lung transplantation
McEvoy et al. An experimental clot model in sheep; generation of a heterologous clot and its detection in vivo using venography and125 I labelled fibrinogen
Nehme et al. Case Report of Intraoperative Anaphylactic Shock and Post-Operative Methemoglobinemia-Cetrimide induced during Hepatic Hydatid Cyst Surgery
Jandik et al. Collateral bronchopulmonary circulation after spontaneous recanalisation of pulmonary thromboemboli in the dog
RU2257199C1 (ru) Способ лечения абсцесса легкого